Can You Have Schizophrenia and Schizoaffective Disorder?

Under current diagnostic systems, schizophrenia and schizoaffective disorder are mutually exclusive diagnoses, meaning a clinician will not assign both to you at the same time. Yet a striking number of people receive one diagnosis and then get reclassified as the other over the course of their illness, sometimes more than once. The boundary between these two conditions has been debated since the 1930s, and the diagnostic overlap is large enough that some researchers question whether the line is real at all.

How the Two Diagnoses Are Separated

Both schizophrenia and schizoaffective disorder involve psychotic symptoms like hallucinations and delusions. The difference, as defined in the DSM-5, hinges on mood episodes and their timing relative to psychosis. When psychotic symptoms happen only during a mood episode (major depression or mania), the diagnosis points toward a mood disorder with psychotic features, not schizoaffective disorder. But when psychosis includes at least a two-week stretch without prominent mood symptoms, the diagnosis can be either schizophrenia or schizoaffective disorder, depending on how much of the illness’s total course is occupied by mood episodes.

In the DSM-5, schizoaffective disorder can only be diagnosed if full mood episodes have been present for the majority of the total active and residual course of the illness, counted from the very first psychotic symptom onward.

¹ That is a high bar. A person with schizophrenia who experiences occasional depressive episodes would not meet it. A person whose depression or mania dominates nearly the entire course of illness, with interspersed periods of standalone psychosis, might.

In practice, though, these temporal judgments are difficult to make. Tracking how much of someone’s illness has been spent in a mood episode versus not requires reliable long-term records and honest self-reporting, both of which can be patchy. Schizoaffective disorder has been described as one of the least stable diagnoses in the DSM system, in large part because of the uncertainty clinicians face when trying to apply the mood-duration criterion.

²

Why People Get Rediagnosed Between the Two

If you or someone you know has been told “you have schizophrenia” at one point and “actually, it’s schizoaffective disorder” at another, that experience is common. Research on diagnostic stability consistently shows that these two diagnoses trade places more often than almost any other pair in psychiatry.

A study following patients over time found a roughly 25% diagnostic change rate across the full sample of people with primary psychotic disorders. Among those changes, people initially diagnosed with schizoaffective disorder most frequently converted to a schizophrenia diagnosis, while many of those initially diagnosed with schizophrenia shifted toward schizoaffective disorder.

³ The traffic runs in both directions, which is telling. If these were truly separate diseases with different underlying causes, you would expect misdiagnosis to run mostly one way as more information accumulates.

Longer-term data paints an even sharper picture. A 50-year national registry study from Denmark found that the reliability between a patient’s first and last schizoaffective diagnosis was only about 60%, compared with 94% for schizophrenia. In other words, people first diagnosed with schizophrenia tended to keep that label, while people first diagnosed with schizoaffective disorder had their diagnosis revised nearly half the time.

⁴ The study also found a substantial group of patients who carried both diagnoses at different points over the decades.

Why is schizoaffective disorder so much less stable? Part of the problem is that mood symptoms naturally wax and wane. A clinician seeing a patient during a depressive episode might conclude the mood component is dominant, while a different clinician seeing the same person six months later, during a psychosis-heavy period, might lean toward schizophrenia. The diagnosis often says as much about the timing of the assessment as it does about the underlying condition.

The Spectrum Debate

The instability of schizoaffective disorder has fueled a decades-old question in psychiatry: are schizophrenia, schizoaffective disorder, and bipolar disorder really separate diseases, or are they different points along a continuum?

The term “schizoaffective disorder” was coined in 1933 by Jacob Kasanin to describe patients who did not fit neatly into the longstanding division between psychotic disorders and mood disorders.

⁵ It was, from the start, a diagnosis designed to handle ambiguity. That origin story still shapes the condition’s identity today. Both the DSM-5 and the ICD-10 retain schizoaffective disorder as its own category, but researchers have consistently questioned whether it represents a genuinely distinct illness.

⁶

When researchers have examined the distribution of psychotic and mood features across large groups of people with serious mental illness, they find no clean dividing line. One study using a dimensional scale spanning from pure schizophrenia-like presentations to pure bipolar-like presentations found significant overlap between all categories, with no clear-cut discontinuity between adjacent diagnostic groups.

⁷ Schizoaffective disorder sits in the muddiest part of that overlap. Some clinicians informally describe it as a “wastebasket diagnosis,” a label applied when someone’s symptoms are too mood-heavy for schizophrenia and too psychotic for a mood disorder.

Neuroimaging work has added another dimension. A study looking at brain structure found that people with schizoaffective disorder and people with schizophrenia showed broadly similar patterns of cortical volume reduction compared to healthy controls, while people with bipolar disorder showed no such reductions.

⁸ At the level of brain anatomy, schizoaffective disorder looks more like schizophrenia than like bipolar disorder. But at the level of symptoms, schizoaffective disorder often looks more like bipolar disorder than like schizophrenia. That paradox has no neat resolution.

More nuanced neuroimaging work has proposed an “expanded continuum” model. This framework suggests a shared psychotic core involving parts of the parietal and frontal brain regions that is common to both schizophrenia and bipolar disorder, alongside separate cognitive and affective components that are impaired to different degrees across the two conditions.

⁹ In that view, schizoaffective disorder is not a separate entity at all but a region of the spectrum where both cognitive and affective impairments overlap substantially.

Shared Genetics Complicate the Picture Further

Family studies have found a clear genetic link between bipolar I disorder, schizoaffective disorder, and schizophrenia. Having a first-degree relative with any one of these conditions raises your risk for the others, not just for the specific diagnosis your relative carries.

¹⁰ That finding is hard to square with the idea that these are three biologically distinct diseases with different genetic architectures.

At the same time, large-scale genetic studies have not been able to pinpoint specific genes that contribute substantially to any one of these conditions in isolation. The genetic risk appears to be distributed across many small-effect variants, many of which are shared across all psychotic disorders. This does not mean the conditions are identical, but it does mean that whatever separates them is unlikely to be a simple on-off genetic switch.

One study examining symptom clusters in the diagnosis of schizoaffective disorder found that its symptoms overlapped 71% with those of schizophrenia and 41% with those of affective (mood) disorders.

¹¹ That heavy tilt toward schizophrenia-like symptoms, combined with substantial mood overlap, again suggests schizoaffective disorder straddles a boundary rather than occupying its own territory.

What This Means for Treatment

If the two diagnoses are this blurry, you might wonder whether it matters which one you get. For treatment purposes, it partly does and partly does not.

Antipsychotic medications are the backbone of treatment for both conditions. For acute flare-ups of schizoaffective disorder, antipsychotics alone appeared to be roughly as effective as combination treatments in research reviews, with some evidence favoring newer atypical antipsychotics. There was also evidence supporting adding antidepressants for people with schizophrenia-spectrum disorders who develop a major depressive episode after their acute psychosis has been controlled, though results were mixed for milder depressive symptoms.

¹²

A practical consequence of the schizoaffective label is that it may open the door to mood stabilizers or antidepressants that would not otherwise be prescribed. Someone diagnosed with schizophrenia alone is less likely to be offered lithium or an antidepressant, even if mood symptoms are present. In that sense, the diagnostic label can influence medication choices even when the underlying biology may be the same.

One notable regulatory difference: paliperidone extended-release has been the only antipsychotic specifically approved in the United States for the treatment of schizoaffective disorder, in addition to its approval for schizophrenia.

¹³ Most other antipsychotics used for schizoaffective disorder are prescribed off-label, based on evidence from schizophrenia trials rather than schizoaffective-specific ones. The scarcity of schizoaffective-specific drug approvals reflects how few clinical trials have studied the condition as a separate entity.

Suicide Risk Deserves Separate Attention

One area where the distinction between the two diagnoses does appear to matter clinically is suicide risk. A large meta-analysis found that the prevalence of attempted suicide was about 47% in people with schizoaffective disorder, compared with about 20% in people with schizophrenia.

¹⁴ That is a striking gap. The rates of completed suicide were closer together (about 2.4% for schizoaffective disorder and 2.0% for schizophrenia), but the attempt rate difference is clinically significant and should inform how aggressively clinicians screen for suicidality.

The mood component of schizoaffective disorder, particularly depression, is the likely driver here. Research has consistently identified a diagnosis of schizoaffective disorder and a history of depression as significantly associated with suicide attempts in people with psychotic disorders.

¹⁵ This is one of the strongest arguments for keeping the schizoaffective label in clinical use even if its biological validity is uncertain: it flags a population at heightened risk for self-harm in a way that a schizophrenia diagnosis alone does not.

When a Dual Diagnosis Gets Documented Anyway

While the DSM-5 does not allow both diagnoses simultaneously, real-world medical records are messier than diagnostic manuals. If you see different clinicians over the years, each working from their own assessment, your chart may contain both labels. Insurance billing codes from different hospital stays might list schizophrenia on one and schizoaffective disorder on another. In practice, plenty of people walk around with records reflecting both conditions, even though no single clinician intends them to coexist.

This matters for insurance coverage, disability determinations, and continuity of care. A new psychiatrist reviewing a chart that lists both diagnoses will typically try to settle on one based on their own evaluation and the available history. But that evaluation depends on what information is available and when in the illness course the person presents, which is exactly why the same person can receive different labels in different settings.

The 50-year Danish registry study as noted earlier identified a discrete group of patients who had carried both diagnoses at different points over the decades, and their clinical profiles differed somewhat from people who had only ever received one or the other.

⁴ This suggests the flip-floppers may not simply be victims of inconsistent clinicians. They may represent people whose illness genuinely sits in the ambiguous zone between the two categories, people for whom neither label is fully accurate.

What a Future Diagnostic System Might Look Like

The schizoaffective concept was invented as a workaround for patients who did not fit existing categories, and it has functioned as a workaround ever since. The question facing psychiatry is whether that workaround should be formalized into something more precise or abandoned in favor of a dimensional approach.

One proposal that has gained traction among researchers is to replace the current categorical system with a spectrum model that scores people along multiple dimensions: severity of psychosis, severity of mood disturbance, cognitive impairment, and functional decline. Under such a system, the question “do I have schizophrenia or schizoaffective disorder?” would be replaced by a profile describing where you fall on each dimension. Some researchers have argued that schizoaffective disorder essentially represents psychotic mood disorders and should not be treated as a separate category from mood disorders with psychotic features at all.

¹⁶

The DSM-5 did make a step in this direction by requiring that mood episodes be present for the “majority” of the illness duration, rather than the vaguer criteria in earlier editions. That change narrowed the schizoaffective category and pushed some people who would have previously received that label into either schizophrenia or a mood disorder with psychotic features. But it did not resolve the underlying problem: human brains do not come with clean labels, and the symptoms of psychosis and mood disturbance interact in ways that resist neat classification.

For people living with either diagnosis, the most practical takeaway is that these labels describe a clinician’s best current reading of your symptom pattern, not a permanent biological stamp. If your diagnosis changes over time, it does not mean the first clinician was incompetent or that your condition has fundamentally shifted. It more likely means you are in the large gray zone where these two categories overlap, and different snapshots of your illness look different depending on when they are taken. The treatment you receive matters more than the label on your chart, and good clinicians treat the symptoms they see regardless of which diagnostic box those symptoms are assigned to.